Vycor Medical (VYCO) Cost of Revenue (2010 - 2026)

Vycor Medical (VYCO) has 17 years of Cost of Revenue data on file, last reported at $83387.0 in Q1 2026.

• On a quarterly basis, Cost of Revenue rose 7.12% year-over-year to $83387.0 in Q1 2026; TTM through Mar 2026 was $307836.0, a 48.25% increase from a year earlier, with the FY2025 full-year figure at $302293.0, up 81.22% from the prior year.
• Cost of Revenue for Q1 2026 stood at $83387.0, up from $81507.0 in the prior quarter.
• Over the last five years, Cost of Revenue for VYCO reached as high as $83387.0 in Q1 2026 and fell as low as $27885.0 in Q2 2022.
• Historically, Cost of Revenue has averaged $49299.0 across 5 years, with a median of $39797.0 in 2023.
• Across the five-year window, Cost of Revenue declined 29.1% in 2022 and soared 130.59% in 2025, its largest moves.
• Year by year, Cost of Revenue stood at $37151.0 in 2022, then increased by 13.11% to $42020.0 in 2023, then jumped by 37.66% to $57844.0 in 2024, then soared by 40.91% to $81507.0 in 2025, then grew by 2.31% to $83387.0 in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $83387.0 in Q1 2026, $81507.0 in Q4 2025, and $61860.0 in Q3 2025.